(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

March 9, 2020

Study Completion Date

September 15, 2021

Conditions
GIST
Interventions
DRUG

avapritinib

Avapritinib tablets for oral administration. Avapritinib will be dosed at 300 mg once daily, continuously.

DRUG

regorafenib

Regorafenib tablets for oral administration. Regorafenib will be dosed at 160 mg once daily for 3 weeks out of every 4 weeks (ie. 3 weeks on/1 week off).

Trial Locations (114)

10065

Memorial Sloan Kettering Cancer Center, New York

15232

UPMC Hillman Cancer Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

20010

Washington Hospital Center - Oncology and Hematology, Washington D.C.

27710

Duke University Medical Center, Durham

30341

Northside Hospital, Atlanta

32224

Mayo Clinic Cancer Center, Jacksonville

33146

University of Miami, Miami

33612

Moffitt Cancer Center, Tampa

37203

Tennessee Oncology, Nashville

43210

Ohio State University, Columbus

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

53226

Medical College of Wisconsin - Froedtert Hospital, Milwaukee

55905

Mayo Clinic Cancer Center, Rochester

60611

Northwestern Medicine, Chicago

60637

The University of Chicago Medical Center, Chicago

63130

Washington University in Saint Louis, St Louis

69008

UNICANCER - Lyon, Centre Léon-Bérard, Lyon

75246

USO - Texas Oncology, Dallas

76210

Texas Oncology - Denton South, Denton

76712

Texas Oncology - Waco, Waco

77030

University of Texas MD Anderson, Houston

80045

University of Colorado Hospital, Aurora

80303

Rocky Mountain Cancer Centers, Boulder

84112

Huntsman Cancer Institute, Salt Lake City

85054

Mayo Clinic Cancer Center, Phoenix

90404

UCLA Hematology/Oncology - Santa Monica, Santa Monica

97239

OHSU - Knight Cancer Institute, Portland

98109

Fred Hutchinson Cancer Research Center, Seattle

99216

Summit Cancer Centers, Spokane

02215

Dana Farber Cancer Institute, Boston

Unknown

Flinders Medical Center, Adelaide

Monash Health, Clayton

The Canberra Hospital, Garran

AKH, Klinik f. Innere Med. I, Onkologie, Vienna

Institut Jules Bordet, Brussels

Leuven Cancer Institute, Leuven

Cross Cancer Institute, Edmonton

Jewish General Hospital, Montreal

Beijing Cancer Hospital, Beijing

Chinese PLA General Hospital, Beijing

West China Hospital Sichuan University, Chengdu

The First Affiliated Hospital of Chongqing Medical University, Chongqing

Fujian Medical University Union Hospital, Fuzhou

The First Affiliated Hospital of Sun Yat-sen University, Guangzhou

The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou

The First Affiliated Hospital, Zhejiang University, Hangzhou

Harbin Medical University Cancer Hospital, Harbin

The First Affiliated Hospital of Nanchang Medical University, Nanchang

Guangxi Medical University Affiliated Tumor Hospital & Oncology Medical College, Nanning

The Affiliated Hospital of Qingdao University, Qingdao

Fudan University Shanghai Cancer Center, Shanghai

Fudan University Zhongshan Hospital, Shanghai

Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai

Liaoning Cancer Hospital & Institute, Shenyang

Tianjin Cancer Hospital, Tianjin

Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Onkologická klinika Fakultní nemocnice Olomouc, Olomouc

Fackultni Nemocnice v Motole, Prague

Institut Bergonié, Bordeaux

Centre Oscar Lambret, Lille

Institute Paoli Calmettes, Marseille

La Timone University Hospital, Marseille

Institut Curie, Paris

Centre Rene Gauducheau, Saint-Herblain

Gustave Roussy Cancer Campus, Villejuif

HELIOS Klinikum Bad Saarow, Bad Saarow

HELIOS Klinikum Berlin-Buch, Berlin

Medizinische Fakultät Carl Gustav Carus, Dresden

Universitaetsklindum Essen, Essen

Universitätsklinikum Frankfurt, Frankfurt

Studienzentrale GbR Lübecker Onkologische Schwerpunktpraxis Dres. med. Uthgenannt, Lübeck

Rupercht-Karls-Universitaet Heidelberg, Mannheim

Fovarosi Onkormanyzat Szent Laszlo Korhaz, Budapest

Magyar Honvédség Egészségügyi Központ Onkológiai Osztály, Budapest

Medical Oncology University Debrecen, Debrecen

University of Pécs, Pécs

Azienda Ospedaliero Universitaria Sant'Orsola Malpighi, Bologna

Candiolo Cancer Institute - FPO, IRCCS, Candiolo

AOUC Azienda Ospedaliero - Universitaria Careggi, Florence

Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan

Istituto Europeo di Oncologia, Milan

Universita degli Studi di Palermo - Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo

Campus Bio-Medico - Oncology Medica, Roma

Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

Radboud University Medical Center, Nijmegen

Erasmus Medical Center, Rotterdam

Sanodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwesytecki w Krakowie, Oddzial Kliniczny Onkologii, Krakow

Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z W-MCO, Olsztyn

Maria Skodowska Curie Memorial Cancer Centre and Institute of Oncology, Warsaw

Dolnoslaskie Centrum Onkologii we Wrocawiu, Wroclaw

National Cancer Centre Singapore, Singapore

Ajou University Hospital, Suwon

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

Hospital de la Santa Creu i Sant Pau, Barcelona

Institut Català d'Oncologia - Hospital Duran i Reynals, Barcelona

Vall d'Hebron, Barcelona

Hospital La Paz, Madrid

Hospital Universitario Gregorio Marañón, Madrid

Hospital Universitario Puerta de Hierro, Madrid

Hospital Virgen del Rocio, Seville

Fundacion Instituto Valenciano de Oncologia, Servicio de Oncologia, Valencia

Hospital Universitario Miguel Servet, Zaragoza

Skanes University Hospital, Lund

Beatson West of Scotland Cancer Centre, Glasgow

Guy's Hospital, London

The Christie NHS Foundation Trust, Manchester

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

M5G 1L7

University Health Network, Toronto

SW3 6JJ

The Royal Marsden Hospital, London

All Listed Sponsors
lead

Blueprint Medicines Corporation

INDUSTRY

NCT03465722 - (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST | Biotech Hunter | Biotech Hunter